Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danshen Oral Liquid is an approved traditional Chinese medicine (TCM) formulation developed and manufactured by Wuhan Juneng Golden Key Pharmaceutical Co., Ltd. The primary active ingredient is derived from *Salvia miltiorrhiza* (Danshen). It is indicated for promoting blood circulation, removing blood stasis, soothing the liver, and relieving depression. Clinically, it is utilized as an adjuvant therapy for cardiovascular symptoms including chest stuffiness, chest tightness, and heartache associated with blood congestion, as well as for the treatment of chronic hepatitis B. The product is registered in China under the National Medicine Standard approval number Z20000096 and is supplied as a 10ml oral solution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danshen Oral Liquid.